IN8BIO, INC. 8-K
Research Summary
AI-generated summary
IN8BIO, Inc. Appoints Kate Rochlin as President; Remains COO
What Happened IN8BIO, Inc. (INAB) announced on a Form 8-K filed February 9, 2026 that its Board of Directors appointed Kate Rochlin, the Company’s Chief Operating Officer, to the additional role of President effective February 4, 2026. Dr. Rochlin will continue to serve as Chief Operating Officer while holding the President title.
Key Details
- Appointment effective date: February 4, 2026; Form 8-K filed February 9, 2026 (Item 5.02 — executive changes).
- Dr. Kate Rochlin will hold both President and Chief Operating Officer roles concurrently.
- Biographical information is available in the Company’s 2025 Proxy Statement (filed April 29, 2025) under “Executive Officers.”
- Company disclosed no family relationships requiring Item 401(d) disclosure and no related-party transactions requiring Item 404(a) disclosure.
Why It Matters This is an internal executive promotion reported as an Item 5.02 executive change on the 8-K. For investors, the appointment signals continuity in management and a formal expansion of Dr. Rochlin’s responsibilities; the filing does not disclose any related-party transactions or family ties, and it does not report changes to compensation or other officers.